JBS Stock Analysis: JBS | NYSE
Packaged Foods | NYSE, USA | Market Cap: 12.498m USD | 12M Return: 10.9% | NL0015002J37 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 65.9M
EPS Trend: 92.9%
Qual. Beats: 0
Rev. Trend: 73.2%
Warnings
Tailwinds
No distinct edge detected
Seasonality 1.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
JBS N.V. is a Netherlands-based, globally diversified food company that processes and markets animal proteins, including beef, pork, lamb, and poultry, while also producing prepared foods and operating ancillary businesses in leather, collagen, hygiene and beauty products, metal packaging, and biodiesel. The company sells a wide portfolio of brands, including Seara, Pilgrims, Moy Park, Friboi, and Swift, and was founded in 1953 with headquarters in Amstelveen.
As a major player in the Packaged Foods & Meats sub-industry of Consumer Staples, JBS operates a vertically integrated business model that spans livestock sourcing, slaughtering, processing, and the production of branded value-added products, which helps it capture margin across the supply chain. Its diversification into byproducts such as leather, collagen, and biodiesel reflects a common industry approach of monetizing the full animal carcass to improve overall unit economics.
- Beef margins tighten as US cattle supply contracts
- Pilgrims poultry volume growth offsets pricing pressure
- Brazilian real volatility pressures BRL-denominated revenue translation
- Seara prepared foods brand drives premium product margin expansion
| Net Income: 6.41b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.36 > 1.0 |
| NWC/Revenue: -11.16% < 20% (prev 6.63%; Δ -17.80% < -1%) |
| CFO/TA 0.29 > 3% & CFO 13.1b > Net Income 6.41b |
| Net Debt (22.8b) to EBITDA (18.8b): 1.21 < 3 |
| Current Ratio: 0.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.02b) vs 12m ago -53.97% < -2% |
| Gross Margin: 11.86% > 18% (prev 14.55%; Δ -2.69% > 0.5%) |
| Asset Turnover: 279.0% > 50% (prev 201.8%; Δ 77.23% > 0%) |
| Interest Coverage Ratio: 2.76 > 6 (EBIT TTM 16.4b / Interest Expense TTM 5.95b) |
| A: -0.93 (Total Current Assets 17.8b - Total Current Liabilities 60.4b) / Total Assets 45.8b |
| B: 0.00 (Retained Earnings 118.5m / Total Assets 45.8b) |
| C: 0.12 (EBIT TTM 16.4b / Avg Total Assets 137b) |
| D: 0.22 (Book Value of Equity 8.22b / Total Liabilities 36.8b) |
| Altman-Z'' = -5.06 = D |
| DSRI: 0.18 (Receivables 3.56b/23.5b, Revenue 382b/460b) |
| GMI: 1.23 (GM 14.55% / 11.86%) |
| AQI: 0.97 (AQ_t 0.26 / AQ_t-1 0.27) |
| SGI: 0.83 (Revenue 382b / 460b) |
| TATA: -0.15 (NI 6.41b - CFO 13.1b) / TA 45.8b) |
| Beneish M = -3.65 (Cap -4..+1) = AAA |
As of October 12, 2026, the stock is trading at USD 12.98 with a total of 6,482,183 shares traded. Over the past week, the price has changed by +11.23%, over one month by +3.18%, over three months by +10.66% and over the past year by +10.92%.
Current recommended Stop Loss: 12.10 (which is 6.8% or 2.1 ATR below the current price).
JBS has received a consensus analysts rating of 4.36. Therefore, it is recommended to buy JBS.
- StrongBuy: 7
- Buy: 5
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 18.1 | 39.1% |
P/E Trailing = 10.9065
P/E Forward = 3.8715
P/S = 0.1371
P/B = 4.6043
Revenue TTM = 382b USD
EBIT TTM = 16.4b USD
EBITDA TTM = 18.8b USD
Long Term Debt = 21.3b USD (from longTermDebt, last quarter)
Short Term Debt = 1.70b USD (from shortTermDebt, last quarter)
Debt = 26.2b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.79b
Net Debt = 22.8b USD (calculated: Debt 26.2b - CCE 3.47b)
Enterprise Value = 35.3b USD (12.5b + Debt 26.2b - CCE 3.47b)
Interest Coverage Ratio = 2.76 (Ebit TTM 16.4b / Interest Expense TTM 5.95b)
EV/FCF = 16.49x (Enterprise Value 35.3b / FCF TTM 2.14b)
FCF Yield = 6.06% (FCF TTM 2.14b / Enterprise Value 35.3b)
FCF Margin = 0.56% (FCF TTM 2.14b / Revenue TTM 382b)
Net Margin = 1.68% (Net Income TTM 6.41b / Revenue TTM 382b)
Gross Margin = 11.86% ((Revenue TTM 382b - Cost of Revenue TTM 337b) / Revenue TTM)
Gross Margin QoQ = 10.83% (prev 10.42%)
Tobins Q-Ratio = 0.77 (Enterprise Value 35.3b / Total Assets 45.8b)
Interest Expense / Debt = 22.67% (Interest Expense 5.95b / Debt 26.2b)
Taxrate = 10.32% (801.5m / 7.77b)
NOPAT = 14.7b (EBIT 16.4b * (1 - 10.32%))
Current Ratio = 0.29 (Total Current Assets 17.8b / Total Current Liabilities 60.4b)
Debt / Equity = 3.19 (Debt 26.2b / totalStockholderEquity, last quarter 8.22b)
Debt / EBITDA = 1.21 (Net Debt 22.8b / EBITDA 18.8b)
Debt / FCF = 10.65 (Net Debt 22.8b / FCF TTM 2.14b)
Total Stockholder Equity = 36.3b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.68% (Net Income 6.41b / Total Assets 45.8b)
RoE = 17.67% (Net Income TTM 6.41b / Total Stockholder Equity 36.3b)
RoCE = 28.49% (EBIT 16.4b / Capital Employed (Equity 36.3b + L.T.Debt 21.3b))
RoIC = 45.28% (NOPAT 14.7b / Invested Capital 32.5b)
WACC = 15.41% (E(12.5b)/V(38.7b) * Re(5.06%) + D(26.2b)/V(38.7b) * Rd(22.67%) * (1-Tc(0.10)))
Discount Rate = 5.06% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -79.70 | Cagr: -29.16%
[DCF] Terminal Value 51.53% ; FCFF base≈4.30b ; Y1≈3.77b ; Y5≈3.04b
[DCF] Fair Price = 0.20 (EV 22.9b - Net Debt 22.8b = Equity 151.8m / Shares 776.1m; r=15.41% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 92.87 | EPS CAGR: 372.8% | SUE: -0.45 | # QB: 0
Revenue Correlation: 73.18 | Revenue CAGR: 9.65% | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.63 | Chg30d=-0.31% | Revisions=-29% | Analysts=6
EPS current Year (2026-12-31): EPS=4.34 | Chg30d=-4.93% | Revisions=-12% | GrowthEPS=-61.8% | GrowthRev=+6.4%
EPS next Year (2027-12-31): EPS=7.07 | Chg30d=+0.86% | Revisions=+12% | GrowthEPS=+62.8% | GrowthRev=+2.3%
[Analyst] Revisions Ratio: -12% (up=6, down=8)